IBIS Therapeutics' SIGNAL© Platform reshapes drug discovery processes. Using state-of-science artificial intelligence, a quarter billion compounds can be screened and then optimized for early safety and efficacy optimization. With a focus on COVID-19 and inflammatory diseases, growth will occur by developing early stage drug candidates through strategic partnerships.